Literature DB >> 33205220

Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage.

Mariana Luna1, Mariana Kamariski1, Iliana Principi1, Victoria Bocanegra2, Patricia G Vallés3,4.   

Abstract

BACKGROUND: Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is the main cause of pediatric acute kidney injury (AKI) in Argentina. Endothelial injury is the trigger event in the microangiopathic process. The host inflammatory response to toxin and E. coli lipopolysaccharide (LPS) is involved in disease pathophysiology.
METHODS: This retrospective study describes pediatric STEC-HUS patients with multiorgan involvement at the initial phase of disease. A retrospective study of critically ill HUS patients with evidence of E. coli infection was conducted through a period of 15 years.
RESULTS: Forty-four patients 35.4 ± 4.1 months were admitted to the intensive care unit for 21 ± 2 days. Mechanical ventilation was required in 41 patients, early inotropic support in 37, and 28 developed septic shock. Forty-one patients required kidney replacement therapy for 12 ± 1 days. Forty-one patients showed neurological dysfunction. Dilated cardiomyopathy was demonstrated in 3 patients, left ventricular systolic dysfunction in 4, and hypertension in 17. Four patients had pulmonary hemorrhage, and acute respiratory distress syndrome in 2. Colectomy for transmural colonic necrosis was performed in 3 patients. Thirty-seven patients were treated with therapeutic plasma exchange, and 28 patients received methylprednisolone (10 mg/kg for 3 days). Of the surviving 32 patients, neurological sequelae were seen in 11 and chronic kidney failure in 5.
CONCLUSIONS: Severe clinical outcome at onset suggests an amplified inflammatory response after exposure to Shiga toxin and/or E. coli LPS. STEC-HUS associated with severe neurological involvement, hemodynamic instability, and AKI requires intensive care and focused therapy.

Entities:  

Keywords:  Children; Kidney replacement therapy; Multiorgan involvement; Neurological compromise; STEC-HUS patients

Mesh:

Substances:

Year:  2020        PMID: 33205220     DOI: 10.1007/s00467-020-04829-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  52 in total

1.  Shiga toxin binding in normal and inflamed human intestinal mucosa.

Authors:  Stephanie Schüller; Robert Heuschkel; Franco Torrente; James B Kaper; Alan D Phillips
Journal:  Microbes Infect       Date:  2006-12-15       Impact factor: 2.700

Review 2.  Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS.

Authors:  Masaki Shimizu
Journal:  Pediatr Int       Date:  2020-01-22       Impact factor: 1.524

3.  Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome.

Authors:  Patricia G Vallés; Silvia Melechuck; Adriana González; Walter Manucha; Victoria Bocanegra; Roberto Vallés
Journal:  Pediatr Nephrol       Date:  2011-10-05       Impact factor: 3.714

4.  Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina.

Authors:  M Rivas; E Miliwebsky; I Chinen; C D Roldán; L Balbi; B García; G Fiorilli; S Sosa-Estani; J Kincaid; J Rangel; P M Griffin
Journal:  Foodborne Pathog Dis       Date:  2006       Impact factor: 3.171

Review 5.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

6.  Postdiarrheal hemolytic and uremic syndrome with severe multiorgan involvement and associated early risk factors.

Authors:  M Oualha; S Pierrepont; P Krug; C Gitiaux; P Hubert; F Lesage; R Salomon
Journal:  Arch Pediatr       Date:  2018-02-01       Impact factor: 1.180

Review 7.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

8.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

9.  Genetic features of human and bovine Escherichia coli O157:H7 strains isolated in Argentina.

Authors:  L Pianciola; B A D'Astek; M Mazzeo; I Chinen; M Masana; M Rivas
Journal:  Int J Med Microbiol       Date:  2016-02-22       Impact factor: 3.473

10.  Risk factors for sporadic Shiga toxin-producing Escherichia coli infections in children, Argentina.

Authors:  Marta Rivas; Sergio Sosa-Estani; Josefa Rangel; Maria G Caletti; Patricia Vallés; Carlos D Roldán; Laura Balbi; Maria C Marsano de Mollar; Diego Amoedo; Elizabeth Miliwebsky; Isabel Chinen; Robert M Hoekstra; Paul Mead; Patricia M Griffin
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

View more
  5 in total

1.  Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial.

Authors:  Alejandro Balestracci; Marina Andrea Capone; Luciana Meni Battaglia; Ismael Toledo; Sandra Mariel Martin; Laura Beaudoin; Jeanette Balbaryski; Lorena Gómez
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

2.  Combined Action of Shiga Toxin Type 2 and Subtilase Cytotoxin in the Pathogenesis of Hemolytic Uremic Syndrome.

Authors:  Romina S Álvarez; Fernando D Gómez; Elsa Zotta; Adrienne W Paton; James C Paton; Cristina Ibarra; Flavia Sacerdoti; María M Amaral
Journal:  Toxins (Basel)       Date:  2021-07-29       Impact factor: 4.546

Review 3.  Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.

Authors:  Izabella de Macedo Henrique; Flavia Sacerdoti; Raissa Lozzardo Ferreira; Camila Henrique; Maria Marta Amaral; Roxane Maria Fontes Piazza; Daniela Luz
Journal:  Front Cell Infect Microbiol       Date:  2022-02-10       Impact factor: 5.293

4.  Secondary Dysfunction of the Intestinal Barrier in the Pathogenesis of Complications of Acute Poisoning.

Authors:  Ju Ju Ivnitsky; T V Schäfer; V L Rejniuk; O A Vakunenkova
Journal:  J Evol Biochem Physiol       Date:  2022-08-28       Impact factor: 1.621

Review 5.  Thrombotic microangiopathy in children.

Authors:  Lilian Monteiro P Palma; Maria Helena Vaisbich-Guimarães; Meera Sridharan; Cheryl L Tran; Sanjeev Sethi
Journal:  Pediatr Nephrol       Date:  2022-01-18       Impact factor: 3.651

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.